People in the study are placed into one of the treatment groups by chance. Treatment is given as intravenous infusion, which means medicine is delivered slowly through a vein. The study is planned to follow people over time while they receive treatment and after treatment ends to see how they do. The trial also watches for side effects, including cytokine release syndrome, a strong immune reaction, and ICANS, which is a group of brain and nerve symptoms that can happen with some immune treatments.

Obrixtamig is also known by the code name BI 764532. It is a type of treatment called a T cell engager, which is designed to help the immune system find and attack cancer cells that have DLL3 on their surface. The study is for previously untreated cancer that is DLL3-positive, meaning the cancer cells have this marker.

The purpose of this research is to determine which treatment approach – either tarlatamab alone or combined with chemotherapy – is more effective in treating these cancers. The study will specifically look at patients whose tumors have already been treated with other therapies and have a certain protein marker called DLL3 on their cancer cells.

During the study, patients will receive their assigned treatment through intravenous infusion. The medications will be given according to a specific schedule, with regular monitoring of the patient’s condition. The treatment period may continue for up to 36 months, depending on how well the treatment works and how well it is tolerated.

The purpose of the study is to understand how well Tarlatamab works in treating these cancers. Tarlatamab is a special type of treatment known as a bispecific T-cell engager (BiTE) molecule, which is designed to help the body’s immune system target and fight cancer cells. The study will involve giving the treatment to patients through an intravenous infusion, which means it will be administered directly into the bloodstream. Some patients may receive a placebo, which is a substance with no active medication, to compare the effects.

Participants in the study will receive the treatment over a period of time, and their response to the treatment will be monitored. This includes looking at how the cancer responds to the treatment and any side effects that may occur. The study aims to gather information on how effective Tarlatamab is in treating these types of cancer and to better understand the body’s response to the treatment. The study will also include biomarker analysis, which involves studying certain biological markers in the body to understand how they relate to the treatment’s effectiveness and any resistance that may develop.

The purpose of the study is to evaluate how effective and safe enfortumab vedotin is when used alone in patients with advanced NEC. Participants in the study will receive the medication over a period of time, and their response to the treatment will be monitored through medical imaging and other assessments. The study will also track how long patients live without the cancer getting worse and how long any positive response to the treatment lasts. Additionally, the study will collect information on any side effects experienced by participants.

This trial is open-label, meaning both the researchers and participants know what treatment is being given. It is a single-arm study, which means all participants receive the same treatment without a comparison group. The study aims to provide valuable information on the potential benefits and risks of using enfortumab vedotin for treating advanced NEC, offering hope for patients who have limited treatment options. The study is expected to continue until 2027, with recruitment starting in late 2024.

The purpose of this study is to develop new ways to predict how long patients with neuroendocrine neoplasms might remain stable without their disease getting worse. This will be done by analyzing measurements from combined scans using both imaging substances. During the study, participants will receive both types of imaging solutions and undergo PET/CT scanning.

Both imaging substances are given as single injections into a vein. 64Cu-DOTATATE attaches to specific receptors found on neuroendocrine tumors, while 18F-FDG helps show how active the tumor cells are. The combination of these two different types of scans provides doctors with more complete information about the tumor’s characteristics and behavior.

The purpose of this study is to determine whether it is possible to perform both imaging methods at the same time to better understand how tumors use energy. During the study, participants will receive two different injectable substances: hyperpolarized [1-13C]pyruvate and Fluor-18-FDG. Both substances will be given through an intravenous injection, and then special images will be taken using a combined PET/MR scanner.

This research will help doctors better understand how tumors process different nutrients and may lead to improved ways of detecting and monitoring cancer. The imaging procedure will be performed once for each participant, and the total dose of each substance has been carefully calculated to ensure safety.

The study will examine how well this treatment works in preventing cancer progression in patients who have advanced or spreading NENs. The medication will be given as oral capsules that patients can take at home. The treatment period may last up to 12 months, with patients taking a daily dose of the medication.

The researchers will monitor how the disease responds to the treatment and track any side effects that may occur. They will also study certain characteristics of the tumors to understand which patients might benefit most from this treatment approach. This includes examining a specific marker called O6-methylguanine-DNA-methyltransferase (MGMT) in the tumor tissue, which may help predict how well the treatment will work.

The purpose of the study is to explore how effective and safe this combination treatment is for patients whose cancer has not responded to standard chemotherapy. Participants in the study will receive either the combination of Cabozantinib and Avelumab or Avelumab alone. The study will last for up to 12 months, during which time the participants’ health and response to the treatment will be closely monitored. Tumor assessments will be conducted every 8 weeks for the first 6 months and then every 12 weeks thereafter to track the progress of the disease.

This trial aims to provide new insights into the treatment of advanced neuroendocrine neoplasias G3, potentially offering new hope for patients with this challenging condition. The study will help determine if the combination of Cabozantinib and Avelumab can better control the disease compared to Avelumab alone. Participants will be monitored for any side effects and changes in their quality of life throughout the study period.

The purpose of this study is to evaluate the safety and effectiveness of different doses of BI 764532 in patients whose cancer has returned or continued to grow after previous treatments. Participants in the study will receive the medication through an intravenous infusion, which means it will be given directly into a vein. The study will monitor how well the treatment works and any side effects that may occur. Some participants may receive a placebo, which is a substance with no active medication, to compare the effects of the treatment.

Throughout the study, participants will have regular check-ups and assessments to track their response to the treatment. The study aims to find the most effective dose of BI 764532 that can help manage these types of cancers while ensuring the safety of the participants. The trial will provide valuable information that could lead to new treatment options for patients with these challenging cancers.

The purpose of the study is to determine which treatment helps patients live longer without the cancer getting worse. Participants will receive one of the two treatments, and their progress will be monitored over time. The study will also involve regular assessments using imaging techniques like CT scans or MRI to measure the size of the cancer and see how it responds to the treatment. Additionally, the study will look at the overall survival of patients and any side effects they may experience from the treatments.

Throughout the study, researchers will also collect information about the cancer’s genetic makeup to identify potential targets for future therapies. This information will help doctors understand how different genetic changes in the cancer might affect the response to treatment. The study is expected to continue until 2029, providing valuable insights into the best treatment options for this challenging type of cancer.